Join Us at EuroPCR 2025 for the RevoEdge Scientific Symposium!
Release time:
2025-04-24
BrosMed Medical cordially invites you to attend our scientific symposium at EuroPCR 2025, held on May 20th at Room 243, Palais des Congrès, Paris.
🔬 Symposium Title: RevoEdge High Pressure Cutting Balloon in PCI: Innovate, Cut, and Conquer!
📅 Date & Time: Tuesday 20 May - 13:15 to 14:15 - Room 243
📍 Location: Room 243, Palais des Congrès, Paris
This highly anticipated session will feature renowned interventional cardiologists from Italy, China, Spain, Malaysia, and Belgium, who will share:
- An in-depth look at the innovative design of RevoEdge – the next-generation high-pressure cutting balloon
- Clinical outcomes and experience with RevoEdge in China
- Case-based discussions offering practical tips and insights for tackling complex lesions
Don’t miss this opportunity to explore how RevoEdge is redefining lesion preparation with precision and power.
Also, visit us at Booth #M20, where we will be showcasing our latest innovations, including the Toolkit for Complex PCI and the RevoEdge high-pressure cutting balloon. Meet our team and discover how BrosMed is advancing interventional cardiovascular care.
We look forward to welcoming you in Paris!
Join Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announces Canadian Approval of RevoEdge™ High-Pressure Cutting Balloon
BrosMed Medical today announced Canadian regulatory approval of the RevoEdge™ High-Pressure Cutting Balloon Dilatation Catheter, expanding the company’s presence in North America and marking another milestone in the global commercialization of its specialty coronary portfolio.
2026-09-14
BrosMed Announced CE MDR Approval of VascuGlide™ Microcatheter System
June 15, 2026-BrosMed is pleased to announce that the VascuGlide™ Microcatheter System has received CE MDR certification, marking another significant milestone in the company's commitment to advancing peripheral intervention solutions.
2026-06-18
